Staphylococcus aureus bacteremia
Conditions
Brief summary
90-day survival without clinical or microbiological failure to treatment or relapse in patients treated with 7 days versus 14 days of antibiotic therapy
Detailed description
All-cause mortality days 14, 28, 90 and 180, Microbiological failure to treatment, Microbiological relapse, Clinical failure to treatment, Severe adverse events grade ≥3, Severe adverse events grade ≥3, Clostridium difficile infection, Multidrug-resistance organism, Health-associated costs associated the treatment lengths, Desirability of outcome ranking (DOOR), Hospital admissions during follow up
Interventions
DRUGBenzylpenicillin ”Panpharma”
DRUGopløsning
DRUGhårde kapsler
DRUGClarithromycin ”Alternova”
DRUGCefuroxim Fresenius Kabi
DRUGPrimcillin
DRUGfilmovertrukne tabletter 800 mg
DRUGGentamicin ”B. Braun”
DRUGinfusionsvæske
DRUGBactocin
DRUGClarithromycin "Accord"
DRUGFlucloxacillin ”Orion”
DRUGCloxacillin "Stragen"
DRUGpulver til injektions-/infusionsvæske
DRUGClindamycin "Abcur"
DRUGDicloxacillin "Alternova"
DRUGPiperacillin/Tazobactam "Sandoz"
DRUGDaptomycin "Accord Healthcare"
DRUGCeftriaxon "Kalceks"
DRUGfilmovertrukne tabletter 400 mg
DRUGAmikacin "Macure"
DRUGinjektionsvæske
DRUGLinezolid Fresenius Kabi
DRUGCefotaxim "MIP"
DRUGMoxifloxacin "Accord"
DRUGPiperacillin/Tazobactam ”Sandoz”
DRUGMeropenem Fresenius Kabi
DRUGMoxifloxacin Fresenius Kabi
DRUGFlucloxacillin "Orion"
DRUGLevofloxacin "Macure"
DRUGLinezolid "Teva"
DRUGtabletter
Sponsors
Hvidovre Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90-day survival without clinical or microbiological failure to treatment or relapse in patients treated with 7 days versus 14 days of antibiotic therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality days 14, 28, 90 and 180, Microbiological failure to treatment, Microbiological relapse, Clinical failure to treatment, Severe adverse events grade ≥3, Severe adverse events grade ≥3, Clostridium difficile infection, Multidrug-resistance organism, Health-associated costs associated the treatment lengths, Desirability of outcome ranking (DOOR), Hospital admissions during follow up | — |
Countries
Denmark
Outcome results
None listed